The company is expecting 2025 EPS to range from $15.25 to $16.25, below the $16.33 FactSet consensus. Revenue is expected to decline by a mid-single-digit percent on a constant currency basis, as ...

Drug maker Gilead (GILD) is rallying 7.5% after the company reported stronger-than-expected fourth-quarter results and provided 2025 earnings per share guidance that came in above analysts ...

While the continued erosion of Biogen’s multiple sclerosis franchise and weaker-than-expected 2025 guidance doesn’t seem to ...

NeuroOne Medical Technologies Corporation ( NASDAQ: NMTC) Q1 2025 Earnings Conference Call February 12, 2025 8:30 AM ET ...

Ketamine also has come under increasing scrutiny as a treatment recently, with studies suggesting that for some patients it ...

A child would need to eat 9,000 cookies in a day to approach harmful levels of pesticide or naturally occurring heavy metals.

Gilead Sciences is rated a Strong Buy due to strong Q4 2024 results and a robust HIV franchise. Check out my 12-month price ...

The tragic early death of "Friends" star Matthew Perry from a ketamine overdose in 2023 has swung a spotlight on th ...

A federal judge on Tuesday ordered the nation’s premier health agencies to restore online access to several websites that monitor HIV, health risks for youths and assisted reproductive technologies, ...

The American Society of Anesthesiologists has issued new guidance on ketamine administration for patients suffering from post-traumatic stress disorder, treatment-resistant depression and other mood ...